Join our May 22nd Micro-Webinar “Reducing the Cost, Complexity and Turnaround Time of mNGS: An Optimized ONT Protocol” at 10:00 am EDT

Finding Answers

We are currently seeking proposals to collaborate on both preclinical and clinical studies. If you have any projects outside these scopes, please feel free to contact us as well.  Our level of support will vary depending on your study so please complete the form below and let us know how we can help.

Pre-Clinical validation research areas of interest:

  1. Effectiveness of our products in the removal of host DNA/RNA
  2. Quantifying the efficiency in isolating the DNA and RNA of multiple kinds of pathogens such as Gram Positive, Gram-Negative, anaerobic pathogens, intracellular bacteria, fungi (yeasts and molds), viral pathogens (RNA/DNA), and parasites
  3. Effectiveness of our product versus existing mNGS strategies that do not implement host DNA depletion
  4. Our products with additional sample types and other infectious diseases (other than whole blood) For example: sputum, BAL, CSF, urine, wound, etc.
  5. Workflow efficiency in unique settings: with smaller or larger volumes, banked or archived specimens or samples such as fresh or frozen samples and in contrast to fresh whole blood volumes (5-10 mls)
  6. PaRTI-Seq in comparison to other assays: (Bacterial culture, PCR, MALDI-TOF, other sequencing strategies, other metagenomic NGS strategies)
  7. Studying with animal models of infection

Clinical validation research must include evaluations of the entire PaRTI-Seq assay, including the Devin filter, Unison  (library preparation), and the PaRTI-Cular (analysis software).

Please note that preclinical validation may be necessary in some cases before proceeding with clinical validation studies. 

  1. Retrospective investigation of archival clinical negative samples, as well as archived positive clinical samples
  2. Clinical utility in specific care settings: ED, ICU, LTC, Transplant ID, etc.
  3. Comparison with other diagnostic methods, specifically blood cultures, PCR, etc.
  4. Devin and PaRTI-Seq and PaRTI-Cular use in for: Microbiome analysis, Epidemiology studies, Surveillance Studies (patient and environmental), Antibiotic Stewardship efforts
  5. Non-human studies: veterinarian, food, and agricultural settings
  6. Basic research applications
  7. Use of Micronbrane products to characterize challenging infections: Infections in special populations ( ex. Immunocompromised pts), Poly-microbic or mixed infections, UTI/ Urosepsis, FUO- Fever of unknown origin, Blood Culture negative, or other assay negative evaluations, Viral infections- RNA and DNA viruses, Patients on empiric antimicrobial therapy, including step-down protocols, GI infections, including C. diff.

Everything metagenomics from collection to action

Get started

Our technologies enrich the understanding of microorganisms through innovative metagenomic collection devices, novel host depletion, NGS-grade reagents, advanced metagenomic sequencing assays, plus rapid bioinformatic software. 

Company
Resources
Find Us

A212, 2F., No. 2, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 302058, Taiwan

© 2024 Micronbrane Medical